ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Update

ADMA Biologics, Inc. (NASDAQ:ADMA) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 17,080,000 shares, a growth of 37.5% from the September 15th total of 12,420,000 shares. Based on an average daily trading volume, of 4,800,000 shares, the short-interest ratio is presently 3.6 days.

Analysts Set New Price Targets

ADMA has been the topic of several research analyst reports. HC Wainwright boosted their price target on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Mizuho increased their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Trading Up 0.8 %

Shares of ADMA Biologics stock opened at $17.15 on Monday. The firm has a 50-day simple moving average of $17.72 and a two-hundred day simple moving average of $12.36. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $21.13. The company has a market cap of $3.98 billion, a P/E ratio of -857.25 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.02) earnings per share. As a group, equities analysts predict that ADMA Biologics will post 0.49 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,900 shares of company stock worth $8,224,121. Corporate insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On ADMA Biologics

A number of large investors have recently added to or reduced their stakes in the stock. LSV Asset Management purchased a new stake in shares of ADMA Biologics during the first quarter worth about $1,028,000. Seven Eight Capital LP purchased a new position in shares of ADMA Biologics in the second quarter valued at approximately $1,992,000. BNP Paribas Financial Markets boosted its stake in shares of ADMA Biologics by 152.2% in the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock worth $4,837,000 after acquiring an additional 442,315 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of ADMA Biologics in the second quarter worth approximately $1,157,000. Finally, Russell Investments Group Ltd. increased its position in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock worth $7,717,000 after purchasing an additional 556,175 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.